


OBESITY MANAGEMENT IN PRIMARY CARE TRAINING AND CERTIFICATE PROGRAM



Applying Foundations of Care When Obesity is the Chief Complaint

Karli Burridge, PA-C, MMS, FOMA
Owner, Gaining Health

AAPA **THE OBESITY SOCIETY** **NACE**

Copyright © 2022 AAPA, TOS, NACE. All rights reserved.

1

Commercial Support

This activity was sponsored by an educational grant from
Novo Nordisk, Inc.

Copyright © 2022 AAPA, TOS, NACE. All rights reserved.

2

Faculty and Disclosure Statement



Karli Burridge is an internationally respected obesity medicine PA. She has received the highest level of training in obesity medicine for PAs, receiving the Certificate of Advanced Education in Obesity Management from the Obesity Medicine Association (OMA), and is a Fellow of OMA. She is the recipient of the 2017 OMA Committee Leadership Award, the 2018 Dr. Vernon B. Astler Award, and the 2020 Dr. Raymond E. Dietz Meritorious Service Award for her contributions to the Obesity Medicine Association.

Karli is heavily involved in educating clinicians to expand the understanding of obesity as a complex chronic disease. She is co-founder and President of PAs in Obesity Medicine, as well as a board member of the Illinois Obesity Society and Chair of the OMA membership committee. She has been a guest lecturer on obesity at several prestigious medical schools, including 4th Yale School of Medicine Online PA Program and Loma Linda University School of Medicine. She has published multiple papers and Clinical Practice Statements in the Obesity Pillars journal and is a co-author of OMA's Obesity Algorithm®.


Karli founded her company, Gaining Health, in 2020 to provide resources and tools for clinicians who want to start or optimize an obesity management program without having to recreate the wheel. More than anything, she appreciates being able to help educate and support other healthcare providers on how to provide optimal evidence-based care for individuals with pre-obesity and obesity.

Disclosures:

- **Consultant:** Novo Nordisk, Bariatric Advantage
- **Advisor:** Gelesis Biotechnology, Currax Pharmaceuticals, Vivus
- **Speaker's Bureau:** Currax Pharmaceuticals, Vivus

Copyright © 2022 AAPA, TOS, NACE. All rights reserved.

3



4

Case 1: Ms. S

MEDICAL BACKGROUND:

- 34-year-old woman with history of gastroesophageal reflux disease (GERD), depression, anxiety, and obesity who presents for an annual visit and advice regarding weight reduction
- No significant change in health over the past year, although feeling more anxious

PSYCHOSOCIAL BACKGROUND:

- Works full time for an advertising agency
- Married for 2 years and wants to start a family; recently saw gynecologist for abnormal menstrual cycle and was told that pregnancy would be more likely if she lost weight

MEDICATIONS:

- Omeprazole 20 mg QD, paroxetine 40 mg QD, alprazolam 0.25 mg prn, and a multivitamin-mineral supplement

Image: © Obesity Action Coalition

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

5

Case 1: Weight History and Past Attempts

Weight history:

- Cyclic and ratcheting weight gain since high school; highest weight is today

Multiple, self-directed weight reduction attempts; mostly temporary crash diets, such as juicing and the hCG diet

- Weight reduction of 10 to 15 pounds each time, followed by weight regain when nutrition changes discontinued
- Viewed the changes as difficult

Not currently following any specific eating or physical activity plan

- States that she tries to make healthy choices

Handwritten notes on graph: "always hit rock bottom then do diets", "teenager college working travelling", "want to have a child"

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

6

Case 1: Physical Examination

- Weight: 203 lbs; height: 67"
• BMI: 32 kg/m²
- Waist circumference: 96 cm
- BP: 126/88 mm Hg; HR: 92 bpm
- Remainder of physical exam unremarkable
- Labs: CBC normal


Chem Profile	Value	Behavioral Screeners
Glucose	102 mg/dL	PHQ-9 10/27
HbA1c	5.8%	Binge Eating Scale 19
TC	210 mg/dL	Self-reported stress 7/10
LDL-C	130 mg/dL	Hours per night of sleep 7-8
TG	150 mg/dL	
HDL-C	40 mg/dL	
TSH	2.2 mIU/L	

BMI, body mass index; BP, blood pressure; CBC, complete blood count; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PHQ, patient health questionnaire; TC, total cholesterol; TG, triglycerides; TSH, thyroid stimulating hormone.

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

7

Components of an Effective Obesity Management Program



Copyright © 2022 AAPA, TCR, NACE. All rights reserved.


8

Obesity Assessment


Weight History and Therapeutic Decision-making

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.


9




10




11




12



13



14



15

Obesogenic Medications

Category	Drugs That May Cause Weight Gain	Possible Alternatives
Neuroleptics	Thioridazine, haloperidol, olanzapine, quetiapine, risperidone, clozapine	Ziprasidone, aripiprazole
Antidiabetic agents	Insulin, sulfonylureas, thiazolidinediones	AGIs, DPP-4i, SGLT2i, GLP-1 RAs, metformin
Steroid hormones	Glucocorticoids, progestational steroids	Barrier methods, NSAIDs
Tricyclics (ADs)	Amiripryline, nortriptyline, imipramine, doxepin	Protriptyline, bupropion, nefazodone
MAOIs (ADs)	Phenelzine	
SSRIs (ADs)	Paroxetine	Fluoxetine, sertraline
Other (ADs)	Mirtazapine, duloxetine	Bupropion
Anticonvulsants	Valproate, carbamazepine, gabapentin, pregabalin, vigabatrin	Topiramate, lamotrigine, zonisamide, felbamate
Antihistamines	Cyproheptadine	Inhalers, decongestants
β- and α-adrenergic blockers	Propranolol, doxazosin, metoprolol	ACEIs, CCBs

ACEIs, angiotensin-converting enzyme inhibitors; ADs, antidepressants; AGIs, Alpha-glucosidase inhibitors; CCBs, calcium channel blockers; DPP-4, Dipeptidyl peptidase-4; GLP-1 RAs, Glucagon-like peptide 1 receptor agonists; MAOIs, monoamine oxidase inhibitors; SGLT2i, Sodium-glucose cotransporter-2 inhibitor; SSRIs, selective serotonin reuptake inhibitors. Kushner RF, et al. JAMA. 2014;312(19):2433-2434. Apovian CM, et al. J Clin Endocrinol Metab. 2015;100(2):342-352.

Copyright © 2017 AAPA, TCR, NACE. All rights reserved.

16


Obesity Assessment

Assessment for Eating Disorders

Copyright © 2017 AAPA, TCR, NACE. All rights reserved.

17

Binge Eating Disorder Screener-7 (BEDS-7)




- During the last 3 months, did you have any episodes of excessive overeating (ie, eating significantly more than what most people would eat in a similar period of time)?
- Do you feel distressed about your episodes of excessive overeating?
- During your episodes of excessive overeating, how often did you feel like you had no control over your eating (eg, not being able to stop eating, feeling compelled to eat, or going back and forth for more food)?

Herman BK, et al. Prim Care Companion CNS Disord. 2016;18(2):10.4088/PCC.15m01896.

Copyright © 2017 AAPA, TCR, NACE. All rights reserved.

18

Binge Eating Disorder Screener-7 (BEDS-7) (cont'd)



- During your episodes of excessive overeating, how often did you continue eating even though you were not hungry?
- During your episodes of excessive overeating, how often were you embarrassed by how much you ate?
- During your episodes of excessive overeating, how often did you feel disgusted with yourself or guilty afterward?
- During the last 3 months, how often did you make yourself vomit as a means to control your weight or shape?

Herman BK, et al. Prim Care Companion CNS Disord. 2016;18(2):10.4088/PCC.15m01896.
Copyright © 2017 AAPA, TCR, NACE. All rights reserved.

19

Binge Eating Disorder (DSM-5)

Criterion 1:	<p>Recurrent episodes of binge eating; an episode of binge eating is characterized by both of the following:</p> <ul style="list-style-type: none"> • Eating, in a discrete period of time (e.g., within any 2-hour period), an amount of food that is definitely larger than most people would eat in a similar period of time under similar circumstances • The sense of lack of control over eating during the episode (e.g., a feeling that one cannot stop eating or control what or how much one is eating)
Criterion 2:	<p>Binge-eating episodes are associated with three (or more) of the following:</p> <ul style="list-style-type: none"> • Eating much more rapidly than normal • Eating until feeling uncomfortably full • Eating large amounts of food when not feeling physically hungry • Eating alone because of being embarrassed by how much one is eating • Feeling disgusted with oneself, depressed, or very guilty after overeating
Criterion 3:	Marked distress regarding binge eating is present
Criterion 4:	The binge eating occurs, on average at least 1 day a week for 3 months (DSM-5 frequency and duration criteria)
Criterion 5:	The binge eating is not associated with the regular use of inappropriate compensatory behavior (e.g., purging, fasting, excessive exercise) and does not occur exclusively during the course of anorexia nervosa or bulimia nervosa
Severity Grading:	<p>Mild: 1 to 3 episodes per week Moderate: 4 to 7 episodes per week Severe: 8 to 13 episodes per week Extreme: 14 or more episodes per week</p>

Copyright © 2017 AAPA, TCR, NACE. All rights reserved.

20

Nutrition Counseling

Nutrition History and Counseling

Copyright © 2017 AAPA, TCR, NACE. All rights reserved.

21

Nutrition History	
<p>Nutrition Recall</p> <ul style="list-style-type: none"> • Short term or long term • 24-hour nutrition recall <ul style="list-style-type: none"> • Quick method to determine patterns, habits, choices • Info: family, social/work environment, socio-economic factors, nutrition understanding • Helps to formulate your shared plan based on your patient's preferences and current nutrition and your nutritional guidance 	<p>Shared Decision-making</p> <ul style="list-style-type: none"> • Improved quality of decision-making process • Establishes context <ul style="list-style-type: none"> • Value and preferences of the patient • Identifies areas of patient uncertainty • Risks and benefits of treatment plans or course of action • Team approach: cohesive therapy approaches
Copyright © 2002 AAPA, TCR, NACE. All rights reserved.	

22

Assessing Knowledge: ASK
<ul style="list-style-type: none"> • “I’d like to learn more about you so that we can formulate a plan that works for YOU, if that’s okay.” • “Let’s go through your typical day. What are some examples of what you would eat for breakfast, lunch, dinner, snacks, etc.? Let’s start with the first thing you eat or drink and go from there.” • “Tell me about the weekends—do you find yourself eating differently?” • “What do you like to drink with your meals throughout the day?” • “Who grocery shops/prepares meals in your house?” • “What does healthy eating mean to you?” • “What types of nutrition plans have you tried in the past? What worked well or didn’t work well for you?” • “Do you (or have you ever) read nutrition labels?”
Copyright © 2002 AAPA, TCR, NACE. All rights reserved.

23

Determining Lifestyle Diet Treatment: ASK	
<p>Your plan</p> <ol style="list-style-type: none"> 1. Meet the patient where he or she is 2. Set realistic expectations with the patient 3. Negative perceptions may lead to clinical inertia 	<p>Ask about past nutritional changes:</p> <ul style="list-style-type: none"> • “What did you like vs what didn’t you like?” • “Why do you think this worked (or didn’t)?” • “What do YOU think your biggest food struggles are?” • “What is your biggest challenge with changing your nutrition?” • “How does your family feel about changing the food at home?”
Copyright © 2002 AAPA, TCR, NACE. All rights reserved.	

24

Set Realistic Expectations

Realistic Weight Reduction Goals	Realistic Nutrition Changes	Realistic Outcomes
1-2 pounds per week	Be wary of restriction/ binge pattern	Find the MIDDLE GROUND (no "all or nothing") Weight reduction may be slower— but less restrictive and more sustainable
10% reduction in 6 months	Limit ultra-processed foods and Promote whole-foods	Focusing on "health behavior goals" as opposed to "scale goals"
"Goal weight" or "ideal weight" may not be achievable and may feel overwhelming	Focus on smaller, attainable goals, focus on "Big Why" and quality of life over # on scale	1) Is it working? 2) Is it sustainable?

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.


25

Provide Resources

- Provide ideas that are easy to implement—small changes add up over time
- Meal and/or snack options
- Grocery lists
- Healthier options when eating out
- Online tools (websites, apps, support, accountability)
- Find and celebrate small successes ("*I only ate one slice of pizza vs the whole pizza*")
- Turn the negative into a positive learning experience: "*You learned something about yourself. You need to have some healthful snacks on hand when you fly so you don't eat airport junk food.*"
- Use other successful patients' eating plans as an example

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

26




27

Physical Activity

Physical Activity History and Counseling

Copyright © 2002 AAPA, TCR, NACE. All rights reserved.

28

Question 


Which of the following is the current recommendation for physical activity?

- A. 120 min low intensity aerobic activity
- B. 150 min moderate intensity aerobic/2 days strength activity
- C. 90 min high intensity aerobic activity
- D. 90 min high intensity aerobic/2 days muscle-strength activity

Copyright © 2002 AAPA, TCR, NACE. All rights reserved.

29

Physical Activity



FITTE

Frequency Intensity Time Type Enjoyment

Copyright © 2002 AAPA, TCR, NACE. All rights reserved.

30


Case 1: Follow-up at 6 Months

- You treat the patient in the office. She chooses to follow a structured lifestyle program and incorporate self-monitoring of her weight, nutrition, and physical activity. She sets a nutrition goal and spends more time planning and preparing her own meals and snacks. You schedule follow-up office visits for monitoring, reinforcement, and counseling.
- Over the next 4 months she successfully loses 6% (12 lbs) of her body weight, but similar to her past history, she experiences weight regain over months 5 and 6. She returns to your office having regained 5 lbs. She is frustrated and more depressed about her weight. She wants to know what else she can do.
- She is monitoring her steps but has not found a consistent way to increase her physical activity.

Copyright © 2002 AAPA, TCR, NACE. All rights reserved.

31

Re-Assess



Copyright © 2002 AAPA, TCR, NACE. All rights reserved.

32

Behavioral Counseling

Copyright © 2002 AAPA, TCR, NACE. All rights reserved.


33

Contextual Logging


Food	Time	Emotion	Hunger (1-10)	Activity
¾ c. Greek yogurt with 5 strawberries and ½ c granola	7:35am	Content, happy	7	Sitting at the kitchen table, thinking about my meeting at 8am.
Coffee with cream and ½ chocolate donut	9:15am	Anxious, frustrated	3	Breakroom at work, meeting didn't go great. Was only planning to have the coffee, but Kim brought donuts and I couldn't resist.
Cobb salad with dressing and piece of bread	12:30pm	More calm	6	Grabbed lunch from the shop downstairs and ate while working at my desk.

Copyright © 2022 AAPA, TDS, NACE. All rights reserved.

34



35



36


Anti-obesity Medications

37

What is the Primary Purpose of Anti-obesity Medications Used in Obesity Treatment?

“The rationale for use of medications is to help patients adhere to a lower calorie diet more consistently in order to achieve more sufficient weight loss and health improvements when combined with increased physical activity.”

Indicated for patients with a BMI ≥ 30 kg/m² or a BMI ≥ 27 kg/m² associated with a comorbidity



Jensen MD, et al. Circulation. 2014;129(25 Suppl 2):S102-113B. Copyright © 2022 AAFP, TCR, NACE. All rights reserved.


38

Current Anti-obesity Medications (AOM)

Agents	Mechanism of Action	Effect
Phentermine	• Sympathomimetic	Appetite regulation
Phentermine/topiramate ER (Qsymia®)	• Sympathomimetic • Anticonvulsant (GABA receptor modulation, carbonic anhydrase inhibition, glutamate antagonism)	Appetite regulation
Naltrexone/bupropion SR (Contrave®)	• Opioid receptor antagonist • Dopamine/noradrenaline reuptake inhibitor	Appetite regulation
Liraglutide (Saxenda®)	• GLP-1 receptor agonist	Appetite regulation
Orlistat (Xenical® or Alli®)	• Pancreatic lipase inhibition	Reduces fat absorption
Semaglutide (Wegovy®)	• GLP-1 receptor agonist	Appetite regulation

Copyright © 2022 AAFP, TCR, NACE. All rights reserved.

39




40

Long-term Management

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

41




42

Finding a Health Psychologist

Behavioral medicine providers (LCSW/PsyD/PhD) within your institution or other medical or clinical settings

- Look for experience with obesity management or eating disorders
- Interventions used: motivational interviewing (MI), cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT)



43

Follow Up (Month 5 and 6)

Diet Fatigue:

- Motivation is not linear
- Praise success, non-scale victories
- Discuss challenges; "troubleshoot"
- Reconnect with goals
- Revisit eating plan
- Try something new



44

Case 2: Mr. T

MEDICAL BACKGROUND:

- 55-year-old man with history of hypertension, type 2 diabetes mellitus, obstructive sleep apnea (OSA), osteoarthritis of the knees, and obesity
- Had a sleeve gastrectomy 10 years ago, initially lost 100 lbs, has regained 50 lbs over the past 5 years, with diabetes and OSA returning with the weight gain

PSYCHOSOCIAL BACKGROUND:

- Married for 20 years, 2 children (ages 13 and 15)
- Working full-time as an insurance salesman
- His wife is also affected by overweight

MEDICATIONS:

- Metformin 500 mg BID, glyburide 10 mg BID, losartan 100 mg QD, diltiazem 240 mg QD, atorvastatin 10 mg QD, aspirin 81 mg QD, chlorthalidone 25 mg QD
- Prescribed CPAP



45

Obesity Assessment

History and Physical Exam

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

46

Case 2: Weight History and Past Attempts

- He has been battling his weight for many decades. He previously lost weight on his own through nutrition changes and exercise, as well as a 100lb weight loss with a sleeve gastrectomy. He has regained 50 lbs from his weight nadir. His diabetes and OSA have returned with the weight gain.
- He attributes his weight gain to pressures at work and at home and having less time to take care of himself. He stopped going to bariatric clinic after his first year after surgery.

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

47

Case 2: Current Health Habits

Nutrition history:

Breakfast	Skipped
Lunch (11:30am)	Restaurant meal with clients
Dinner (7pm)	At home, with family, large portion sizes
Snacks	Up late, watching TV and snacking after family goes to bed

- Physical activity is limited to activities of daily living
- Currently very few hobbies; spends most of his off-time watching TV, reading magazines, or talking with family
- Previously active in photography and volunteering

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

48

Case 2: Physical Examination

- Weight: 278 lbs; height: 70"; BMI: 40 kg/m²
- BP: 128/62 mm Hg
- HR: 92 bpm
- Heart: Grade 2/6 SEM at apex
- Extremities: dystrophic skin changes, 1+ edema

Labs		Behavioral Screeners	
FBS	95 mg/dL	PHQ-9	2/27
HbA1c	6.9%	Binge Eating Scale	13
BUN	19 mg/dL	Self-reported stress	4/10
TC	152 mg/dL	Hours per night of sleep	5-7 hours - feels unrefreshed / not using CPAP
LDL-C	80 mg/dL		
TG	181 mg/dL		
HDL-C	38 mg/dL		

BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; FBS, fasting blood sugar; SEM, systolic ejection murmur.
Copyright © 2022 AAFP, TCR, NACE. All rights reserved.

49

Improvements in Risk Factors and Comorbidities

	Orlistat ¹	Phentermine/topiramate ER ²	Naltrexone/bupropion SR ³	Liraglutide 3.0 mg ⁴	Semaglutide 2.4 mg ⁵
WC	↓	↓	↓	↓	↓
BP	↓	↓	↓	↓	↓
LDL	↓↓	↓	↑	↓	↓
HDL	↑	↑	↑	↑	↑
TG	↓↓	↓↓	↓	↓	↓
A1C	↓	↓	↓	↓↓	↓↓
HR	↓	-	↑	↑	↑
Diabetes	↓↓	↓	↓	↓↓	↓↓

WC, waist circumference.
1. Orlistat prescribing information. http://www.gene.com/download/pdf/orlistat_prescribing.pdf. 2. Phentermine/topiramate ER prescribing information. <https://aspria.com/pdf/prescribing-information.pdf>. 3. Naltrexone SR/bupropion SR prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/20140300s0001a.pdf. 4. Liraglutide 3.0 mg prescribing information. <http://novi-pi.novintest.com/xaenda.pdf>. 5. Semaglutide prescribing information. <http://www.novo-pi.com/wegovy.pdf>.
Copyright © 2022 AAFP, TCR, NACE. All rights reserved.

50

Surgery and Devices for Weight Reduction and Management

Bariatric Surgery

Procedures

- Roux-en-Y - gastric bypass (RYGB)
- Gastric sleeve
- Biliopancreatic diversion with duodenal switch
- Revisional surgery

Devices

- Gastric balloon
- Gastric emptying system

Medical Devices

- Oral space occupying device
- Stomach space occupying device

Copyright © 2022 AAFP, TCR, NACE. All rights reserved.

51

Bariatric/Metabolic Surgery


52

Considerations for Surgical Treatment

<p>May be an option for patients with:</p> <ul style="list-style-type: none"> • BMI 35-39.9 kg/m² and ≥1 obesity-related comorbidity • BMI ≥40 kg/m² 	<p>Long-term reduction in:</p> <ul style="list-style-type: none"> • Body weight • Cardiovascular biomarkers, events • Other weight-related complications <p><i>Need for ongoing support and intervention</i></p>
---	--

Jensen MD, et al. Circulation. 2014;129(25 Suppl 2):S102-6138. Arterburn DE, et al. Br Med J. 2014;349:g3961. Toh SY, et al. Nutrition. 2009;25(11-12):1150-1156. Copyright © 2022 AAPA, TCR, NACE. All rights reserved.


53



54

RYGB Results in Durable Remission of T2DM in Most (but not all) Patients

- Retrospective cohort study of 4434 adults with T2DM who underwent RYGB
- Lower remission rates predicted by poor preoperative glycemic control (A1c $\geq 6.5\%$), longer duration of diabetes, and receiving insulin
- Median time to relapse was 8.3 y



Arterburn DE, et al. *Obes Surg*. 2013;23(1):99-102

Copyright © 2007 AAPA, TOS, NACE. All rights reserved.

55

Case 2: Follow Up

- You discuss all options with the patient.
- He attends a group discussion of revisional bariatric surgery but says, "I want to try something less aggressive."
- He is not taking a bariatric multivitamin—agrees to have labs checked and re-start a bariatric-specific multivitamin.
- He agrees to work on his nutrition and agrees to the use of meal replacement products for greater calorie and portion control. He is started on a 1500-calorie diet.
- He is not interested in increasing physical activity.
- He also agrees to discuss possible medications to aid in his nutrition efforts.
- You tell him that his diabetes medications may need monitoring during weight reduction.

Copyright © 2007 AAPA, TOS, NACE. All rights reserved.

56

Obesity and Sleep

Copyright © 2007 AAPA, TOS, NACE. All rights reserved.

57

Night Eating Syndrome—DSM-5


Technically: Other Specified Feeding or Eating Disorder (OSFED)

- Criterion 1:** The daily pattern of eating demonstrates a significantly increased intake in the evening and/or nighttime, as manifested by one or both of the following:
 - At least 25% of food intake is consumed after the evening meal
 - At least two episodes of nocturnal eating per week
- Criterion 2:** Awareness and recall of evening and nocturnal eating episodes are present.
- Criterion 3:** The clinical picture is characterized by at least three of the following features:
 - Lack of desire to eat in the morning and/or breakfast is omitted on four or more mornings per week
 - Presence of a strong urge to eat between dinner and sleep onset and/or during the night
 - Sleep onset and/or sleep maintenance insomnia are present four or more nights per week
 - Presence of a belief that one must eat in order to initiate or return to sleep
 - Mood is frequently depressed and/or worsens in the evening
- Criterion 4:** The disorder is associated with significant distress and/or impairment in functioning.
- Criterion 5:** The disordered pattern of eating has been maintained for at least 3 months.
- Criterion 6:** The disorder is not secondary to substance abuse or dependence, medical disorder, medication, or another psychiatric disorder.

Copyright © 2002 APA, ICS, NACE. All rights reserved.

58

Sleep and Obesity



Cooper CB, et al. *BMJ Open Sport & Exercise Medicine*. 2018;4:e000392. Wu Y, et al. *Sleep Medicine*. 2014;15(12):1456-1462. Copyright © 2002 APA, ICS, NACE. All rights reserved.

59

Nutrition Counseling

Meal Replacement

Copyright © 2002 APA, ICS, NACE. All rights reserved.

60

Meal Replacements

- **Meal Replacements:** liquid meals, meal bars, calorie-controlled packaged meals
- **Supporting Evidence:** *Substituting one or two daily meals or snacks with meal replacements is a successful weight reduction and weight maintenance strategy.*
- **Most Overheard Concerns:** Processed foods... consider the alternative

Look for Foods with:

- Kcal: 150-400
- Fiber: Min 3-5 g
- Sugar: <5 g
- Protein: At least 15 g
- Trans Fat: 0g



Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

61

ADW: Meal Replacements




Frontier CHICKEN FAJITA BOWL
CHICKEN, CHICKEN BROILERS WITH QUINOA, MEXICAN PEAS, CREAMY PICO DE GALLO, MEXICAN SAUCE, GUACAMOLE, QUESO, AVOCADO

Nutrition Facts
Serving size 1 bowl (320g)

Calories 260

Total Fat 15g	30%
Sodium 10g	20%
Total Sugar 10g	20%
Total Protein 15g	30%
Total Fiber 3g	6%
Total Fat 15g	30%
Total Sugar 10g	20%
Total Protein 15g	30%
Total Fiber 3g	6%

INGREDIENTS CHICKEN BROILERS, CHICKEN BROILERS WITH QUINOA, MEXICAN PEAS, CREAMY PICO DE GALLO, MEXICAN SAUCE, GUACAMOLE, QUESO, AVOCADO



CHIPOTLE MEXICAN GRILL

THIS MEXICAN SOUTH FAVORITE IS OUR FAVORITE OVER OUR FAVORITE MEXICAN POBLANO

GOURI

YOUR BURRITO BOWL



Calories

Calories from Fat	480
Calories	1020
Total Fat	53.5g
Saturated Fat	13.7g
Trans Fat	0g
Protein	55g
Carbohydrates	79g
Sodium	13g
Sugar	7g
Fiber	190mg

VITAMINS & MINERALS

Vitamin A	50%
Vitamin C	125%
Calcium	30%
Iron	30%

62

Barriers to Implementation

- Eating out with clients
 - How likely is this to change?
- Large portions at dinner
 - Level of Hunger
- **Timing Rule of Thumb:**
 - Try to avoid long periods of time with no eating occasions
 - 4-5 hours
 - Overly hungry, hard to control portions, less energy, vulnerable to unhealthy choices
- **Other suggestions for better choices?**

Patient's Nutrition Recall

Breakfast	Skipped
Lunch (11:30am)	Restaurant meal with clients
Dinner (7pm)	At home, with family, large portion sizes
Snacks	Up late, watching TV and snacking after family goes to bed

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

63

Case 2

- Through shared decision-making, the patient chooses to try liraglutide 3.0 mg and you provide a prescription. He is instructed on pen use and drug administration, including titration over the first month.
- Over the next 6 months, he loses 22 lbs (8% of initial body weight). Weight is now 256 lbs. New BMI = 36.8 kg/m² (Class II obesity)
- Labs:
 - Glucose: 102 mg/dL
 - A1C: 6.2%
 - TC: 174 mg/dL
 - LDL-C: 104 mg/dL
 - HDL-C: 51 mg/dL
 - TG: 95 mg/dL
- Weight and labs remain stable over an additional 6 months

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

64

Benefits of Modest Weight Reduction

Greater Benefits with Greater Weight Reduction


Measures of glycemia ¹		-3%
Triglycerides ¹		
HDL cholesterol ¹		
Systolic and diastolic blood pressure		
Hepatic steatosis measured by MRS ²		
Measures of feeling and function:		-5%
Symptoms of urinary stress incontinence ³		
Measures of sexual function ^{4,5}		
Quality of life measures (IWQOL) ⁶		
NASH Activity Score measured on biopsy ⁷		
Apnea-hypopnea index ⁸	-10%	
Reduction in CV events, mortality, remission of T2DM	-15%	

IWQOL, Impact of Weight on Quality of Life; MRS, magnetic resonance spectroscopy; NASH, non-alcoholic steatohepatitis.
 1. Wing et al. Diabetes Care. 2011;34:1481-1486. 2. Lazo et al. Diabetes Care. 2010;33:2156-2163. 3. Phelan et al. Urol. 2012;187:939-944. 4. Wing et al. Diab Care. 2012;35:2307-2344. 5. Wing et al. Journal of Sexual Medicine. 2010; 7:156-165. 6. Crosby, Manual for the IWQOL-Lite Measure. 7. Promrat et al. Hepatology. 2010;51:1212-129. 8. Foster et al. Arch Intern Med. 2005;165:1619-1626.

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

65

Key Take-aways



- 01 Obesity is a multifaceted disease, which often requires multiple providers participating in care
- 02 Patients need a comprehensive assessment prior to initiating care
- 03 Obesity management is a dynamic process and requires ongoing assessment
- 04 Treatment includes a continuum of care, including lifestyle management, pharmacotherapy, and surgery
- 05 Be aware of the role of mental health, both in how symptoms impact health habits and how medications may be playing a role in maintaining obesity
- 06 Consider referring to a specialized obesity treatment program for challenging cases

Copyright © 2022 AAPA, TCR, NACE. All rights reserved.

66
